How does Cosentyx (secukinumab) affect vaccine effectiveness?
Cosentyx (secukinumab) is an immunomodulating monoclonal antibody that blocks interleukin-17A (IL-17A). Because it changes immune signaling, it can affect how strongly the body responds to some vaccines, particularly those that rely on intact immune activation to generate antibodies and other immune responses.
Guidance for patients on Cosentyx generally emphasizes vaccinating before starting treatment when possible, and using the correct vaccine type while on therapy. In practice, clinicians pay extra attention to whether a vaccine is live versus non-live, since live vaccines are typically avoided during treatment with immune-modifying drugs.
What happens with live vaccines vs non-live vaccines on Cosentyx?
The key distinction is vaccine type:
Live vaccines (which contain weakened forms of a pathogen) are generally not recommended for people taking immunomodulators like Cosentyx because of the risk that the weakened pathogen could cause disease if the immune response is suppressed.
Non-live vaccines (often inactivated, recombinant, or subunit formats) are generally considered usable, and the main question becomes whether Cosentyx reduces the strength of the immune response. For many immunomodulators, non-live vaccines still generate protection, but antibody levels and clinical effectiveness can be lower than in people not receiving the drug.
Does Cosentyx reduce antibody levels after vaccination?
Cosentyx targets IL-17A, which plays a role in host defense and immune signaling. Blocking IL-17A can blunt parts of the immune response that contribute to antibody production and functional immunity after vaccination. The direction of the effect (reduced response strength) is the main concern clinicians consider when advising timing and vaccine choice.
Whether that translates into a clinically meaningful drop in protection depends on:
the specific vaccine,
the person’s baseline immune status,
the timing of vaccination relative to starting or pausing therapy, and
how the immune system of that patient responds despite IL-17 blockade.
When is the best time to vaccinate relative to starting or pausing Cosentyx?
A common approach is:
vaccinate before starting Cosentyx when feasible, so the immune system can build a response without IL-17A blockade,
and avoid live vaccines altogether during treatment.
If you’re already on Cosentyx and a new vaccine is needed, clinicians typically decide based on vaccine type and urgency (for example, routine vaccines versus travel vaccines), while following the safety rules for live vaccines and the patient’s overall risk.
Do people on Cosentyx need extra doses or boosters?
Because immune responses can be weaker with some immunomodulating therapies, clinicians may recommend following standard vaccine schedules plus any additional booster guidance that applies to immunocompromised or immune-modified patients. The exact need for additional doses depends on:
local public-health recommendations,
the vaccine in question, and
how you’re classified clinically (for example, based on the therapy and overall immune risk).
Practical guidance for patients getting vaccines while on Cosentyx
Before getting vaccinated, people taking Cosentyx should:
confirm with their clinician or pharmacist that the vaccine is non-live,
share that they take secukinumab and their dosing schedule,
ask whether timing adjustments are needed (especially for vaccines recommended before immunosuppression), and
make sure routine vaccines are up to date, including seasonal and age- or risk-based vaccines.
Are there differences by condition (psoriasis vs psoriatic arthritis vs ankylosing spondylitis)?
The drug is the same in each condition, so the immunologic mechanism is the same. The difference is usually not the effect of Cosentyx itself, but the patient’s baseline health, disease activity, other medications used alongside Cosentyx, and overall immune risk. Those factors can influence how strong a vaccine response is in real-world use.
What sources discuss Cosentyx and vaccine responses?
This answer focuses on the general immunology and clinical safety logic for IL-17A blockade and vaccine-type risk (live vs non-live). If you want, tell me which vaccine you’re asking about (for example, flu, COVID-19, shingles, pneumococcal, HPV) and your age and whether you’re on any other immune-modifying medications, and I can tailor the guidance to that specific vaccine type and scenario.